Merriman Curhan Ford Downgrades XOMA Ltd. (XOMA) to Neutral; Going Concern Gives Us Pause
XOMA Hot Sheet
Rating Summary:2 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Merriman Curhan Ford downgrades XOMA Ltd. (Nasdaq: XOMA) to Neutral. Lowers target range from $1.50-2.50 to $1.50-2.00.
Merriman analyst says, "Our investment thesis is that we perceive XOMA as a revitalized business model with multiple opportunities. The company’s development risk is spread across royalties from approved products, a growing internal pipeline and a broad technology platform in antibody discovery, development and manufacturing. Additionally, XOMA has been obtaining contracts from the U.S. government for developing antibodies for biodefense."
XOMA Ltd. is a biopharmaceutical company focused on the discovery, development and manufacture of therapeutic antibodies.
Merriman analyst says, "Our investment thesis is that we perceive XOMA as a revitalized business model with multiple opportunities. The company’s development risk is spread across royalties from approved products, a growing internal pipeline and a broad technology platform in antibody discovery, development and manufacturing. Additionally, XOMA has been obtaining contracts from the U.S. government for developing antibodies for biodefense."
XOMA Ltd. is a biopharmaceutical company focused on the discovery, development and manufacture of therapeutic antibodies.
You May Also Be Interested In
Create E-mail Alert Related Categories
DowngradesRelated Entities
Merriman Curhan FordSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
